J&J’s Zytiga Slows Prostate Cancer While Easing Pain in Study

Johnson & Johnson’s prostate cancer pill Zytiga, currently given after chemotherapy fails, significantly slows tumor growth, prevents pain and lengthens life when used earlier, researchers said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.